ILMN vs. PACB
Compare and contrast key facts about Illumina, Inc. (ILMN) and Pacific Biosciences of California, Inc. (PACB).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: ILMN or PACB.
Key characteristics
| ILMN | PACB | |
|---|---|---|
| YTD Return | 7.92% | -79.82% |
| 1Y Return | 54.13% | -72.58% |
| 3Y Return (Ann) | -26.88% | -58.40% |
| 5Y Return (Ann) | -13.30% | -15.82% |
| 10Y Return (Ann) | -1.82% | -11.63% |
| Sharpe Ratio | 1.52 | -0.59 |
| Sortino Ratio | 2.28 | -0.53 |
| Omega Ratio | 1.25 | 0.93 |
| Calmar Ratio | 0.76 | -0.71 |
| Martin Ratio | 4.44 | -1.00 |
| Ulcer Index | 13.95% | 69.09% |
| Daily Std Dev | 40.69% | 116.87% |
| Max Drawdown | -96.14% | -97.65% |
| Current Drawdown | -71.37% | -96.13% |
Fundamentals
| ILMN | PACB | |
|---|---|---|
| Market Cap | $23.41B | $670.58M |
| EPS | -$9.97 | -$1.31 |
| PEG Ratio | 0.71 | -0.17 |
| Total Revenue (TTM) | $4.39B | $133.18M |
| Gross Profit (TTM) | $2.81B | $19.12M |
| EBITDA (TTM) | $1.43B | -$206.13M |
Correlation
The correlation between ILMN and PACB is 0.38, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
ILMN vs. PACB - Performance Comparison
In the year-to-date period, ILMN achieves a 7.92% return, which is significantly higher than PACB's -79.82% return. Over the past 10 years, ILMN has outperformed PACB with an annualized return of -1.82%, while PACB has yielded a comparatively lower -11.63% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
ILMN vs. PACB - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Illumina, Inc. (ILMN) and Pacific Biosciences of California, Inc. (PACB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
ILMN vs. PACB - Dividend Comparison
Neither ILMN nor PACB has paid dividends to shareholders.
Drawdowns
ILMN vs. PACB - Drawdown Comparison
The maximum ILMN drawdown since its inception was -96.14%, roughly equal to the maximum PACB drawdown of -97.65%. Use the drawdown chart below to compare losses from any high point for ILMN and PACB. For additional features, visit the drawdowns tool.
Volatility
ILMN vs. PACB - Volatility Comparison
The current volatility for Illumina, Inc. (ILMN) is 8.50%, while Pacific Biosciences of California, Inc. (PACB) has a volatility of 30.27%. This indicates that ILMN experiences smaller price fluctuations and is considered to be less risky than PACB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
ILMN vs. PACB - Financials Comparison
This section allows you to compare key financial metrics between Illumina, Inc. and Pacific Biosciences of California, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities